Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
This article was originally published in The Pink Sheet Daily
Executive Summary
Fee rates for biosimilars could be decoupled from new drug user fees in order to provide more predictable revenue stream.